CN101721456B - Antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases and method for preparing phospholipid complex formulation thereof - Google Patents
Antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases and method for preparing phospholipid complex formulation thereof Download PDFInfo
- Publication number
- CN101721456B CN101721456B CN 201010106612 CN201010106612A CN101721456B CN 101721456 B CN101721456 B CN 101721456B CN 201010106612 CN201010106612 CN 201010106612 CN 201010106612 A CN201010106612 A CN 201010106612A CN 101721456 B CN101721456 B CN 101721456B
- Authority
- CN
- China
- Prior art keywords
- liquid
- ethanol
- medicine
- radix puerariae
- rhizoma chuanxiong
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases, comprising the following components of szechuan lovage rhizome, the root of kudzu vine, Panax notoginsenosides and red yeast rice. The method for preparing phospholipid complex formulation of the antiatherosclerotic Chinese traditional medicincomprises (1) preparation of dry extract of the root of kudzu vine, (2) preparation of szechuan lovage rhizome oil and dry extract of Ligusticum wallichii and (3) preparation of formulation. By enriching effective parts of medicinal materials, the purity of effective components of the antiatherosclerotic Chinese traditional medicine is enhanced greatly, thereby meeting the request of formulation. The invention is formed by trial of medicinal effectiveness separation and innovation of the medicine and realizes organic combination of traditional formulation process and modern pharmaceutical technology, thereby not only enhancing medicine-loading rate but also enhancing bioavailability of medicine used by a human body.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation and preparation method thereof, refer in particular to and to treat cardiovascular and cerebrovascular disease and antiatherogenic Chinese medicine preparation, be specially a kind of Chinese medicine of atherosclerosis treatment cardiovascular and cerebrovascular disease and the preparation method of phospholipid complex formulation thereof.
Background technology
Society is due to the quickening of rhythm of life, and unhealthy life style is popular, and the cardiovascular and cerebrovascular disease sickness rate rises year by year, and the trend of rejuvenation is arranged, prevalence, disability rate and the highest disease of mortality rate have been become, the serious health that is threatening people and life.Therefore controlling spreading of cardiovascular and cerebrovascular disease becomes the task of top priority.The main inducing of cardiovascular and cerebrovascular disease is atherosclerosis, in case atherosclerosis has occured, As time goes on be easy to occur cardiovascular and cerebrovascular disease, and atherosclerosis is the pathological change that is caused by many factors, and one or more the factor of controlling wherein all will be conducive to reduce the sickness rate of cardiovascular and cerebrovascular disease.Selecting the little Drug therapy primary disease of good effect side reaction is optimum selection, and Chinese medicine has these advantages, at the employ new technology flourish today new medicine preparation of atherosclerosis treatment cardiovascular and cerebrovascular disease of exploitation high-efficiency low-toxicity of science and technology, will point the day and await for it.
At present, the Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease is of a great variety, yet due to a variety of causes, as curative effect, absorption, drug loading etc., restrict the development of the Chinese medicine preparation of existing treatment cardiovascular and cerebrovascular disease, can not satisfy well patient's actual demand, solving patient's slight illness.
Summary of the invention
The present invention is directed to the problems referred to above of the Chinese medicine preparation existence of existing treatment cardiovascular and cerebrovascular disease, a kind of Chinese medicine of atherosclerosis treatment cardiovascular and cerebrovascular disease and the preparation method of phospholipid complex formulation thereof are provided.
To achieve these goals, the present invention has adopted following technical scheme: the Chinese medicine of a kind of atherosclerosis treatment cardiovascular and cerebrovascular disease is comprised of the component of following percentage by weight: Rhizoma Chuanxiong 59%-79%, Radix Puerariae 17%-37%, Radix Notoginseng total arasaponins 0.1%-1%, Monas cuspurpureus Went 1%--5%.
In order to maximize the curative effect of above-mentioned Chinese medicine, improve its drug loading and absorbance, through inventor's experimental exploring for many years, the preparation method of having invented the phospholipid complex formulation of above-mentioned Chinese medicine:
(1) preparation of Radix Puerariae dry extractum
the Radix Puerariae pulverizing medicinal materials of above-mentioned percentage ratio is become coarse powder, alcohol reflux with 70% three times, each reflux extracting time is 1--3 hour, then the extracting solution with three gained merges, through reclaim under reduced pressure ethanol wherein and after concentrating, form once concentration liquid, again once concentration liquid thin up is become every milliliter of upper prop liquid that contains 0.2g Radix Puerariae medical material, upper prop liquid is by after macroporous adsorptive resins, discard upper prop liquid, then wash resin column with water to sugar-free, with 10 times of 30% ethanol elution resins to the resin column volume, collect eluent, after decompression recycling ethanol, form liquid to be made, liquid to be made is concentrated, vacuum drying, just get dry extract, pulverize, standby.
(2) preparation of Rhizoma Chuanxiong oil and Rhizoma Chuanxiong dry extract is ground into coarse powder with the Ligusticum chuanxiong Hort of above-mentioned percentage ratio, adding 85% ethanol soaked 20--26 hour at ambient temperature, then with the speed percolation of 3%--9% per hour, collect 6 times to the percolate of Ligusticum chuanxiong Hort weight, after reclaiming the ethanol in percolate, separatory is treated in formation, to treat the separatory static layering, upper strata liquid is through extracting the refining Rhizoma Chuanxiong oil that obtains, the subnatant thin up becomes every milliliter of upper prop liquid that contains the 1g Ligusticum chuanxiong Hort, make upper prop liquid by after macroporous adsorptive resins, discard upper prop liquid, then wash resin column with water to sugar-free, with 6 times of 65% ethanol elution resins to the resin column volume, form eluent, collect eluent, form liquid to be made after reclaim under reduced pressure ethanol wherein, liquid to be made is concentrated, vacuum drying, just get the Rhizoma Chuanxiong dry extract, pulverize, standby.
(3) preparation process
Take the Monas cuspurpureus Went powder of above-mentioned percentage ratio, after adding appropriate alcohol dipping, the Radix Notoginseng total arasaponins, Rhizoma Chuanxiong dry extract and the Radix Puerariae dry extractum ethanol that add above-mentioned percentage ratio, add again the lecithin ethanol, mixing also stirs, and decompression recycling ethanol is concentrated, add corresponding disintegrating agent according to existing preparation process, namely can be made into phospholipid complex formulation.
Chinese medicinal ingredients is complicated, and effective ingredient is many, has the effect of many target spots, but its contained active component is often on the low side, reach clinical Expected Results, also needs the other side's Chinese crude drug to discard the dross and select the essential, and the effective site in medical material has been carried out enrichment and purification.
The present invention's process is to medicinal material extract, concentrated, enrichment and purification, effective ingredient purity improves greatly, can satisfy the preparation needs, simultaneously, consider the weakness that exists on the active ingredient of Chinese herbs self property, active component is more difficult by the biomembrane barrier, can affect the performance of its curative effect to a certain extent, limit its application clinically.
The research of phosphatide complexes in recent years enjoys attention, and phosphatide complexes is the comparatively stable material that medicine and phospholipid molecule form by the charge migration effect.After medicine and phospholipid form complex, physics and chemistry fat, biologic activity etc. all can occur to change significantly, show the characteristic different from the parent medicine, the change of physicochemical property such as fat-soluble obvious enhancing, the change of biologic activity are stronger than parent drug as the activity of phosphatide complexes, bioavailability is higher, toxic and side effects is less.
Phosphatide complexes is regarded as a breakthrough in traditional medicine field, and Phospholipid Complex with Active Constituents from Chinese Materia all has important theoretical and practical significance for the modernization of accelerating Chinese medicine compound preparation, raising Chinese medicine preparation technical merit and clinical application quality.After making phosphatide complexes as Semen Ginkgo extrac, blood pressure lowering and antiinflammatory action all significantly strengthen, this preparation phosphatide complexes, not only fat-soluble enhancing, drug effect strengthen but also drug powder good fluidity, nonhygroscopic, drug loading is large, does not need to add adjuvant, directly compressible and encapsulated.
Consider effective ingredient Lovastatin, the puerarin in the dried cream of ferulic acid, Radix Puerariae in Rhizoma Chuanxiong extract and the saponins in Radix Notoginseng total arasaponins in Chinese crude drug Monas cuspurpureus Went of the present invention, all has certain polarity, has the possibility that forms complex with lecithin, in order to improve drug effect of the present invention, obtained the phosphatide complexes of above four kinds of compositions through test, solubility test shows that the Monas cuspurpureus Went ethanol extraction is insoluble to petroleum ether, and Monas cuspurpureus Went phospholipid dissolves in petroleum ether after compound; The dried cream of Rhizoma Chuanxiong is insoluble to chloroform and after compound with lecithin, its dried cream dissolves in chloroform; The dried cream of Radix Puerariae is insoluble to chloroform, and the dried cream after compound with lecithin dissolves in chloroform; Dried cream after same Radix Notoginseng total arasaponins and phospholipid are compound also dissolves in chloroform, fat-soluble all enhancings greatly.Measure above each composition in dried cream with the compound mistake of lecithin with the method for Lovastatin, ferulic acid, puerarin and the Radix Notoginseng total arasaponins of compound mistake not measured, all can detect, and recall rate is all more than 95%, although compound rear fat-soluble enhancing is described, but do not form novel compound, and recombination rate is all more than 95%.Due to the composition of every kind of extract in the middle of above four kinds of extracts more complicated all, except four kinds of compositions that detected, other compositions also might form phosphatide complexes, but after anyway forming phosphatide complexes with lecithin, lecithin can promote medicine to enter cell from the intestinal epithelial cell membrane that hydrophilic environment shifts by the lipophilic environment better as pharmaceutical carrier, arrive at last blood, play a role.
The present invention is that the inventor is on the basis of years'experiences, form by the drug effect side's of tearing open the test innovation to our medicine again, realized the combination of conventional formulation technique and modern pharmaceutical technology, not only improved drug loading but also improved the bioavailability of human body to medicine.Below be the drug effect of the present invention side's of tearing open test:
One, test objective
To three kinds of Chinese medicines in the present invention: Radix Notoginseng total arasaponins (A), Rhizoma Chuanxiong (B), Radix Puerariae (C) extract, every kind of extract is set two dosage, adopt orthogonal design, take the Banded Rats bilateral common carotid arteries copy the acute complete cerebral ischemic model and measure brain water content and cerebral index as index, find out best compatibility.
Two, test material
1, medicine
Trematodiasis rhizome of chuanxiong capsule, 0.3g/ grain (3 of adult's consumptions one time, 2 times on the one 0.06g/kg/ days) is produced lot number: 090101. by Shanxi Qian Hui pharmaceutcal corporation, Ltd
XUESAITONG PIAN 0.1g/ grain (1 of adult's consumption one time, 3 times on the one 0.005g/kg/ days) is produced lot number: 20080906 by the Yunnan Province Yuxi City Weihe Pharmaceutical Co.ltd
Radix Notoginseng total arasaponins, Rhizoma Chuanxiong, Radix Puerariae extract are provided by magnificent pharmaceutical companies of a specified duration.
2, animal
The Wistar rat, male and female half and half, body weight 250-300g is provided by Shandong Traditional Chinese Medicine University's Experimental Animal Center, the quality certification number: SYXK (Shandong) 20050043.
3, instrument
Thermostatic drying chamber (202A-1, state Rui Shiyanyiqichang), electronic balance (JA2004, Shanghai balance equipment factory)
Three, method
According to table 1, use L
8(2
7) the orthogonal table experiment arrangement, wherein Radix Notoginseng total arasaponins, Rhizoma Chuanxiong, Radix Puerariae extract are respectively A, B and C, and every kind of extract is set two dosage (being low dosage 1 and high dose 2).Test is established 12 groups, the 1st group of Radix Notoginseng total arasaponins: Rhizoma Chuanxiong altogether: three kinds of medicine proportionings of Radix Puerariae are 1: 1: 1; The 2nd group of Radix Notoginseng total arasaponins: Rhizoma Chuanxiong: three kinds of medicine proportionings of Radix Puerariae are 1: 1: 2; The 3rd group of Radix Notoginseng total arasaponins: Rhizoma Chuanxiong: three kinds of medicine proportionings of Radix Puerariae are 1: 2: 1; The 4th group of Radix Notoginseng total arasaponins: Rhizoma Chuanxiong: three kinds of medicine proportionings of Radix Puerariae are 1: 2: 2; The 5th group of Radix Notoginseng total arasaponins: Rhizoma Chuanxiong: three kinds of medicine proportionings of Radix Puerariae are 2: 1: 1; The 6th group of Radix Notoginseng total arasaponins: Rhizoma Chuanxiong: Radix Puerariae three medicine proportionings are 2: 1: 2; The 7th group of Radix Notoginseng total arasaponins: Rhizoma Chuanxiong: three kinds of medicine proportionings of Radix Puerariae are 2: 2: 1; The 8th group of Radix Notoginseng total arasaponins: Rhizoma Chuanxiong: three kinds of medicine proportionings of Radix Puerariae are 2: 2: 2 (wherein 1 is 7.5 times of adult's quantities, and 2 is 15 times); The 9th group is trematodiasis rhizome of chuanxiong Capsules group (7.5 times of adult's quantities); The 10th group is XUESAITONG group (7.5 times of adult's quantities), is gastric infusion; The 11st group is model group; The 12nd group is sham operated rats, and sham-operation and model group are to the equivalent normal saline, and 1 times/day, administration is 7 days altogether.
Brain water content and cerebral index are measured: the last administration is after 1 hour, pentobarbital sodium anesthesia, the ligation bilateral common carotid arteries forms incomplete cerebral ischemic model, after ligation 4 hours, open cranium and get brain, weigh, calculate cerebral index (heavy * 100/ body weight of cerebral index=brain), then roasting to constant weight at 110 ℃ of baking ovens, calculate brain water content %=(cutaneous horn weight-brain stem is heavy)/cutaneous horn heavy * 100%.
Table 1 factor level table
Four, result
See Table 2, table 3, table 4.
Table 2 each treated animal brain water content and cerebral index
Annotate: with the sham operated rats ratio
△ △P＜0.01,
△P＜0.05; With the model group ratio
※P＜0.05
The single factor statistics of table 3 scale
The A medicine
Dependent Variable: brain water content
The B medicine
Dependent Variable: brain water content
The C medicine
Dependent Variable: brain water content
Table 4A, B, C three medicine compatibility analysiss of variance table
Dependent Variable: brain water content
| Source | Type III Sum of | df | Mean Square | F | Sig. |
| Squares | |||||
| Corrected Model Intercept A B C Error Total Corrected Total | .442(a) 50648.692 .052 .288 .101 .109 50649.243 .551 | 3 1 1 1 1 4 8 7 | .147 50648.692 .052 .288 .101 .027 | 5.432 1866587 .755 1.928 10.629 3.740 | .068 .000 .237 .031 .125 |
a R Squared＝.803(Adjusted R Squared＝.655)
Table 5 brain water content orthogonal experiments is analyzed
Therefore three kinds of medicines improve the animal pattern cerebral edema and reduce brain water content effect B＞C＞A, wherein B (P＜0.05=significance, adding C effect has downward trend, but the animal brain water content is added up nonsignificance.Three kinds of medicine high doses (2) effect simultaneously all is better than low dosage (1).Comprehensive various factors, B is principal agent as can be known, A
2B
2C
2Be best compatibility program, for further verifying its prescription correctness, can further observe by other tests of pesticide effectiveness.
The specific embodiment
Embodiment 1: the Chinese medicine of a kind of atherosclerosis treatment cardiovascular and cerebrovascular disease is comprised of the component of following percentage by weight: Rhizoma Chuanxiong 59%, Radix Puerariae 37%, Radix Notoginseng total arasaponins 0.5%, Monas cuspurpureus Went 3.5%.
The preparation method of the phospholipid complex formulation of above-mentioned Chinese medicine:
(1) preparation of Radix Puerariae dry extractum
the Radix Puerariae pulverizing medicinal materials of above-mentioned percentage ratio is become coarse powder, alcohol reflux with 70% three times, each reflux extracting time is 1 hour, then the extracting solution with three gained merges, through reclaim under reduced pressure ethanol wherein and after concentrating, form once concentration liquid, again once concentration liquid thin up is become every milliliter of upper prop liquid that contains 0.2g Radix Puerariae medical material, and make upper prop liquid pass through macroporous adsorptive resins, discarded post liquid, the washed resin post is to sugar-free, with 10 times of 30% ethanol elution resins to the resin column volume, collect eluent, form liquid to be made after reclaim under reduced pressure ethanol wherein, liquid to be made is concentrated, vacuum drying, just get dry extract, pulverize, standby.
(2) preparation of Rhizoma Chuanxiong oil and Rhizoma Chuanxiong dry extract is ground into coarse powder with the Ligusticum chuanxiong Hort of above-mentioned percentage ratio, adding 85% ethanol soaked 20 hours at ambient temperature, then with 3% speed percolation per hour, collect 6 times to the percolate of Ligusticum chuanxiong Hort weight, after reclaiming the ethanol in percolate, separatory is treated in formation, to treat the separatory static layering, upper strata liquid is through extracting refining Rhizoma Chuanxiong oil, the subnatant thin up becomes every milliliter of upper prop liquid that contains the 1g Ligusticum chuanxiong Hort, upper prop liquid is by after macroporous adsorptive resins, discard upper prop liquid, wash resin column with water to sugar-free, with 6 times of 65% ethanol elution resins to column volume, collect eluent, form liquid to be made after reclaim under reduced pressure ethanol wherein, liquid to be made is concentrated, vacuum drying, just get the Rhizoma Chuanxiong dry extract, pulverize, standby.
(3) preparation preparation
Take the Monas cuspurpureus Went powder of above-mentioned percentage ratio, after adding appropriate alcohol dipping, the Radix Notoginseng total arasaponins, Rhizoma Chuanxiong dry extract and the Radix Puerariae dry extractum ethanol that add above-mentioned percentage ratio, add again the lecithin ethanol, stir mixing, decompression recycling ethanol, concentrated, add corresponding disintegrating agent according to existing preparation process, namely can be made into phospholipid complex formulation.
Can make red rhizome of chuanxiong capsule:
Take the Monas cuspurpureus Went powder of above-mentioned percentage ratio, add 10 times to the ethanol of Monas cuspurpureus Went powder weight, dipping is 40 minutes under the condition of 60 ℃, and then add Radix Notoginseng total arasaponins, Rhizoma Chuanxiong dry extract and the Radix Puerariae dry extractum ethanol of above-mentioned percentage ratio, then add lecithin ethanol, mixing, stirred 10 minutes under the condition of 30 ℃, decompression recycling ethanol, concentrated, vacuum drying, add disintegrating agent, pulverize, sieve, encapsulated and get final product.
Embodiment 2: the Chinese medicine of a kind of atherosclerosis treatment cardiovascular and cerebrovascular disease is comprised of the component of following percentage by weight: Rhizoma Chuanxiong 79%, Radix Puerariae 17%, Radix Notoginseng total arasaponins 1%, Monas cuspurpureus Went 3%.
The preparation method of the phospholipid complex formulation of above-mentioned Chinese medicine:
(1) preparation of Radix Puerariae dry extractum
the Radix Puerariae pulverizing medicinal materials of above-mentioned percentage ratio is become coarse powder, alcohol reflux with 70% three times, each reflux extracting time is 2 hours, then the extracting solution with three gained merges, through reclaim under reduced pressure ethanol wherein and after concentrating, form once concentration liquid, again once concentration liquid thin up is become every milliliter of upper prop liquid that contains 0.2g Radix Puerariae medical material, and make upper prop liquid pass through macroporous adsorptive resins, discarded post liquid, the washed resin post is to sugar-free, with 10 times of 30% ethanol elution resins to the resin column volume, collect eluent, form liquid to be made after reclaim under reduced pressure ethanol wherein, liquid to be made is concentrated, vacuum drying, just get dry extract, pulverize, standby.
(2) preparation of Rhizoma Chuanxiong oil and Rhizoma Chuanxiong dry extract is ground into coarse powder with the Ligusticum chuanxiong Hort of above-mentioned percentage ratio, adding 85% ethanol soaked 24 hours at ambient temperature, then with 6% speed percolation per hour, collect 6 times to the percolate of Ligusticum chuanxiong Hort weight, after reclaiming the ethanol in percolate, separatory is treated in formation, to treat the separatory static layering, upper strata liquid is through extracting the refining Rhizoma Chuanxiong oil that obtains, the subnatant thin up becomes every milliliter of upper prop liquid that contains the 1g Ligusticum chuanxiong Hort, upper prop liquid is crossed macroporous adsorptive resins, discarded post liquid, the washed resin post is to sugar-free, with 6 times of 65% ethanol elution resins to column volume, collect eluent, form liquid to be made after reclaim under reduced pressure ethanol wherein, liquid to be made is concentrated, vacuum drying, just get the Rhizoma Chuanxiong dry extract, pulverize, standby.
(3) preparation preparation
Take the Monas cuspurpureus Went powder of above-mentioned percentage ratio, after adding appropriate alcohol dipping, the Radix Notoginseng total arasaponins, Rhizoma Chuanxiong dry extract and the Radix Puerariae dry extractum ethanol that add above-mentioned percentage ratio, add again the lecithin ethanol, mixing also stirs, and decompression recycling ethanol is concentrated, add corresponding disintegrating agent according to existing preparation process, namely can be made into phospholipid complex formulation.
Can make red rhizome of chuanxiong soft capsule:
take above-mentioned percentage ratio Monas cuspurpureus Went powder, add 10 times to the ethanol of Monas cuspurpureus Went powder weight, dipping under 60 ℃ of conditions 40 minutes, centrifugal, medicinal residues are used 5 times of ethanol to the Monas cuspurpureus Went powder weight again, and repeated impregnations is once under the condition of 60 ℃, merge centrifugal liquid, add above-mentioned percentage ratio Radix Notoginseng total arasaponins, Rhizoma Chuanxiong oil and Radix Puerariae dry extractum ethanol, add again the lecithin ethanol, mixing, stirring under 30 ℃ of conditions 10 minutes, decompression recycling ethanol, concentrated, add adjuvant palmitic acid oil 10%, peak cured 5%, supply final quantity with vegetable oil, make suspension, be pressed into soft capsule automatically rolling on the film machine.Through washing ball, drying, polishing, packing and get final product.
Embodiment 3: the Chinese medicine of a kind of atherosclerosis treatment cardiovascular and cerebrovascular disease is comprised of the component of following percentage by weight: Rhizoma Chuanxiong 60%, Radix Puerariae 35%, Radix Notoginseng total arasaponins 1%, Monas cuspurpureus Went 4%.
The preparation method of the phospholipid complex formulation of above-mentioned Chinese medicine:
(1) preparation of Radix Puerariae dry extractum
the Radix Puerariae pulverizing medicinal materials of above-mentioned percentage ratio is become coarse powder, alcohol reflux with 70% three times, each reflux extracting time is 3 hours, then the extracting solution with three gained merges, through reclaim under reduced pressure ethanol wherein and after concentrating, form once concentration liquid, again once concentration liquid thin up is become every milliliter of upper prop liquid that contains 0.2g Radix Puerariae medical material, upper prop liquid passes through macroporous adsorptive resins, discard upper prop liquid, the washed resin post is to sugar-free, with 10 times of 30% ethanol elution resins to the resin column volume, collect eluent, form liquid to be made after reclaim under reduced pressure ethanol wherein, liquid to be made is concentrated, vacuum drying, just get dry extract, pulverize, standby.
(2) preparation of Rhizoma Chuanxiong oil and Rhizoma Chuanxiong dry extract is ground into coarse powder with the Ligusticum chuanxiong Hort of above-mentioned percentage ratio, adding 85% ethanol soaked 26 hours at ambient temperature, then with 9% speed percolation per hour, collect 6 times to the percolate of Ligusticum chuanxiong Hort weight, after reclaiming the ethanol in percolate, separatory is treated in formation, to treat the separatory static layering, upper strata liquid is through extracting refining Rhizoma Chuanxiong oil, the subnatant thin up becomes every milliliter of upper prop liquid that contains the 1g Ligusticum chuanxiong Hort, after upper prop liquid is crossed macroporous adsorptive resins, discard upper prop liquid, the washed resin post is to sugar-free, with 6 times of 65% ethanol elution resins to column volume, collect eluent, form liquid to be made after reclaim under reduced pressure ethanol wherein, liquid to be made is concentrated, vacuum drying, just get the Rhizoma Chuanxiong dry extract, pulverize, standby.
(3) preparation preparation
Take the Monas cuspurpureus Went powder of above-mentioned percentage ratio, after adding appropriate alcohol dipping, the Radix Notoginseng total arasaponins, Rhizoma Chuanxiong dry extract and the Radix Puerariae dry extractum ethanol that add above-mentioned percentage ratio, add again the lecithin ethanol, mixing also stirs, and decompression recycling ethanol is concentrated, add corresponding disintegrating agent according to existing preparation process, namely can be made into phospholipid complex formulation.
Can make red rhizome of chuanxiong sheet:
Take the Monas cuspurpureus Went powder of above-mentioned percentage ratio, add 10 times to the ethanol of Monas cuspurpureus Went powder weight, dipping is 40 minutes under the condition of 60 ℃, add Radix Notoginseng total arasaponins, Rhizoma Chuanxiong dry extract and the Radix Puerariae dry extractum ethanol of above-mentioned percentage ratio, then add lecithin ethanol, mixing, stirred 10 minutes under the condition of 30 ℃, decompression recycling ethanol, concentrated, vacuum drying, add disintegrating agent, pulverize, sieve, tabletting and get final product.
Disintegrating agent is prior art, as carboxymethyl starch sodium, low substituted hydroxy-propyl methylcellulose, gas-producing disintegrant etc.
Macroporous adsorptive resins can be the AB-8 type.
Claims (1)
1. the Chinese medicine of atherosclerosis treatment cardiovascular and cerebrovascular disease, it is characterized in that: the component by following weight forms: Rhizoma Chuanxiong extract 75mg, Radix Puerariae extract 199.5mg, Radix Notoginseng total arasaponins 75mg;
Wherein, Rhizoma Chuanxiong extract is prepared from by following methods:
Ligusticum chuanxiong Hort is ground into coarse powder, adding 85% ethanol soaked 24 hours at ambient temperature, then with every little out-of-date 6% speed percolation, collect 6 times to the percolate of Ligusticum chuanxiong Hort weight, after reclaiming the ethanol in percolate, separatory is treated in formation, to treat the separatory static layering, upper strata liquid is through extracting the refining Rhizoma Chuanxiong oil that obtains, the subnatant thin up becomes every milliliter of upper prop liquid that contains the 1g Ligusticum chuanxiong Hort, make upper prop liquid by AB-8 type macroporous adsorptive resins, discarded post liquid, then wash resin column with water to sugar-free, with 6 times of 65% ethanol elution resins to the resin column volume, collect eluent, form liquid to be made after reclaim under reduced pressure ethanol wherein, liquid to be made is concentrated, vacuum drying, just get Rhizoma Chuanxiong extract,
Wherein, Radix Puerariae extract is prepared from by following methods:
the Radix Puerariae pulverizing medicinal materials is become coarse powder, alcohol reflux with 70% three times, each reflux extracting time is 2 hours, then the extracting solution with three gained merges, through reclaim under reduced pressure ethanol wherein and after concentrating, form once concentration liquid, again once concentration liquid thin up is become every milliliter of upper prop liquid that contains 0.2g Radix Puerariae medical material, upper prop liquid is by after AB-8 type macroporous adsorptive resins, discarded post liquid, then wash resin column with water to sugar-free, with 10 times of 30% ethanol elution resins to the resin column volume, collect eluent, after decompression recycling ethanol, form liquid to be made, liquid to be made is concentrated, vacuum drying, just get Radix Puerariae extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010106612 CN101721456B (en) | 2010-01-30 | 2010-01-30 | Antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases and method for preparing phospholipid complex formulation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010106612 CN101721456B (en) | 2010-01-30 | 2010-01-30 | Antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases and method for preparing phospholipid complex formulation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101721456A CN101721456A (en) | 2010-06-09 |
| CN101721456B true CN101721456B (en) | 2013-06-12 |
Family
ID=42443407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010106612 Expired - Fee Related CN101721456B (en) | 2010-01-30 | 2010-01-30 | Antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases and method for preparing phospholipid complex formulation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101721456B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103372051B (en) * | 2012-04-20 | 2015-04-15 | 北京北大维信生物科技有限公司 | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition |
| CN105641509A (en) * | 2016-01-14 | 2016-06-08 | 吕海峰 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
| CN111213882A (en) * | 2020-03-11 | 2020-06-02 | 北京康立生医药技术开发有限公司 | Plant mixed extraction process and application thereof |
| CN116035210B (en) * | 2022-12-30 | 2024-08-20 | 广州白云山汉方现代药业有限公司 | Method for solving layering of content and application of method in preparation of plant sterol ester red yeast soft capsules |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167773A (en) * | 2006-10-27 | 2008-04-30 | 冯仗林 | Medicine composition for treating cardiac and cerebral vascular diseases |
-
2010
- 2010-01-30 CN CN 201010106612 patent/CN101721456B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167773A (en) * | 2006-10-27 | 2008-04-30 | 冯仗林 | Medicine composition for treating cardiac and cerebral vascular diseases |
Non-Patent Citations (1)
| Title |
|---|
| 孙燕等.中药活性成分磷脂复合物研究进展.《医学综述》.2007,第13卷(第11期),第875-877页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101721456A (en) | 2010-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101411761B (en) | Novel use of plants in sorbus malus group of malus | |
| CN102423352B (en) | Preparation method of Chinese medicinal granules for treating cardio-cerebrovascular diseases | |
| CN102114102B (en) | Traditional Chinese medicine extract mixed preparation and application thereof | |
| CN101721456B (en) | Antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases and method for preparing phospholipid complex formulation thereof | |
| CN103169788B (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| WO2008007063A2 (en) | Anti-obesity product and it's method of preparation | |
| CN102014931A (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN102100825A (en) | Chinese medicine composition for treating pains and preparation method thereof | |
| CN102319289B (en) | Hyperglycemic Chinese medicinal composition comprising cinnamon polyphenol and the like and preparation method of hyperglycemic Chinese medicinal composition | |
| CN101214250B (en) | Use of hederagenin and its derivatives in preparing antidepressant product | |
| CN102614280B (en) | Chinese medicinal composition with blood fat reducing effect, and preparation method and application thereof | |
| CN1327859C (en) | Schisandra fruit extractive, its preparation process and purposes | |
| CN1989984B (en) | Chuanxiong rhizome effective ingredient, preparing method, preparation and use thereof | |
| KR101375483B1 (en) | Ginseng prosapogenin high concentration containing Sanchi ginseng preparation using sonication and process for thereof | |
| CN103316074B (en) | Medicine composite of halenia corni extract, astragalus extract and liquorice extract as well as preparation and application of medicine composite | |
| CN102976943B (en) | The alpha-crystal form material of salvianolic acid A, method for making and pharmaceutical composition and purposes | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN101020016A (en) | Medicine for treating fracture and injured tendon and its prepn | |
| CN114288331A (en) | Method for simultaneously extracting volatile oil from effective parts of total flavonoids and total saponins of Chinese medicinal fenugreek, extract and application thereof | |
| CN102599501B (en) | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver | |
| CN1318034C (en) | Drug prepared by mulberry bark extract | |
| CN1994426B (en) | Preparation method, and identification and assaying method of 'Sheng Mai' soft capsule | |
| CN101259179A (en) | Chinese medicine 'naodesheng' soft capsule and preparation thereof | |
| CN102743712A (en) | Medicine composition for hepatitis | |
| CN1418690A (en) | Erigeron breviscapus compound medicament and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130612 Termination date: 20160130 |
|
| EXPY | Termination of patent right or utility model |